Rakuten Medical Secures $100 Million in Series F Funding
Rakuten Medical, Inc. has recently raised $100 million in an oversubscribed Series F financing round, showcasing the remarkable confidence investors have in the company’s innovative approach to cancer treatment. This financing round was not only significant in terms of the amount raised but also because it attracted the largest number of institutional investors in the history of Rakuten Medical. The round was led by the TaiAx Life Science Fund, a prominent player in the life science sector, highlighting the international interest the company has garnered.
Use of Funds to Accelerate Development
The funds raised through this Series F effort will be primarily directed towards supporting the company's pivotal global Phase 3 trial of its flagship investigational drug, ASP-1929. This trial is a vital step toward gaining U.S. FDA approval, with the company targeting a Biologics License Application submission by 2028. The management at Rakuten Medical believes that with these funds, they can enhance patient enrollment across multiple countries such as the U.S., Taiwan, Japan, and others.
Innovative Cancer Treatment Approach
ASP-1929 is part of Rakuten Medical’s Alluminox® platform and represents an advanced photoimmunotherapy treatment targeting a specific cancer antigen, EGFR. This drug is currently being investigated in combination with pembrolizumab for the treatment of recurrent head and neck cancer. The company is enthusiastic that this innovative modality could provide new options for patients facing such challenging conditions.
Expanding Global Reach with New Developments
Beyond head and neck cancer, Rakuten Medical is ambitiously expanding its development programs possibly making inroads into other cancers, including solid tumors and gynecologic cancers. The company plans to initiate new trials, supported by grants, to explore the efficacy of ASP-1929 in these newer areas. Such diversification could significantly increase the global impact of its therapies.
Strategic Partnerships Drive Growth
The success of this financing was bolstered by a diverse array of investors, including significant Japanese institutions and Taiwanese venture firms. These partnerships will not only provide capital but also strategic insights and regulatory guidance essential for navigating different international markets. Rakuten Medical’s investors include major firms such as Daiwa Securities and Sumitomo Mitsui Banking, which adds a layer of confidence and credibility to the company’s efforts.
Accomplishments and Future Goals
Mickey Mikitani, CEO of Rakuten Medical, expressed that this investment signifies a strong vote of confidence in the company’s differentiated technology. The Alluminox® platform is designed to accelerate the development of innovative therapies, underlining the company’s commitment to advancing cancer treatments. In addition, with well-established offices across multiple countries, Rakuten Medical is poised to scale its operations effectively by leveraging local knowledge and resources.
Innovation Through Investment
According to Michael Huang of Taiwania Capital Management, the oversubscription of the Series F financing indicates an important belief in Rakuten Medical’s ability to meet significant medical needs with its technologies. This enthusiastic support from a global syndicate of investors reinforces the notion that Rakuten Medical is heading in the right direction with its pursuit of novel treatment modalities.
About Rakuten Medical
Rakuten Medical, Inc. is dedicated to developing and commercializing its Alluminox® platform-based photoimmunotherapy. This innovative approach has shown promise in clinical settings and aims to conquer cancer by making advanced treatments widely accessible. With a company ethos centered around patient welfare, Rakuten Medical is passionately pursuing its mission to develop transformative therapies that can help patients worldwide.
Frequently Asked Questions
What is ASP-1929?
ASP-1929 is an investigational cancer treatment developed by Rakuten Medical, utilizing the Alluminox® platform and targeting tumors through photoimmunotherapy.
What will the raised funds be used for?
The funds will support the global Phase 3 trial of ASP-1929 and enhance operational capabilities for patient enrollment across several countries.
Who led the Series F financing?
The Series F financing was led by TaiAx Life Science Fund, which attracted a diverse group of institutional investors.
What is the goal for the U.S. FDA approval?
Rakuten Medical aims to submit a Biologics License Application to the FDA for ASP-1929 by 2028.
Where does Rakuten Medical have offices?
Rakuten Medical has offices in several regions, including the U.S., Japan, Taiwan, Switzerland, and India, facilitating a global approach to cancer treatment.
